Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Crown

Showing results (21-30 of 202) with videos related to

Pageof 21
Sort By:
Oncotarget|December 3, 2014
ADAM10 and ADAM17: New players in trastuzumab tesistanceMichael J Duffy, John Crown, Maeve Mullooly
Seminars in Cancer Biology|July 6, 2020
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancerNicola Gaynor, John Crown, Denis M Collins
Methods in Molecular Biology (Clifton, N.J.)|September 8, 2011
Analysis of gene expression as relevant to cancer cells and circulating tumour cellsAnne M Friel, John Crown, Lorraine O'Driscoll
Investigational New Drugs|January 28, 2025
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630Minhong Tang, John Crown, Michael J Duffy
Targeted Oncology|August 15, 2025
MYC as a Target for Cancer Treatment: from Undruggable to Druggable?Michael J Duffy, Minhong Tang, John Crown
Medical Oncology (Northwood, London, England)|July 14, 2022
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cellsShane O'Grady, John Crown, Michael J Duffy
The Oncologist|May 27, 2004
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experienceJohn Crown, Michael O'Leary, Wei-Seong Ooi
Breast Cancer Research and Treatment|March 23, 2018
Mutant p53 in breast cancer: potential as a therapeutic target and biomarkerMichael J Duffy, Naoise C Synnott, John Crown
Clinical Chemistry and Laboratory Medicine|April 15, 2021
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?Michael J Duffy, Eleftherios P Diamandis, John Crown
International Journal of Cancer|May 15, 2012
Targeted therapy for triple-negative breast cancer: where are we?Michael J Duffy, Patricia M McGowan, John Crown
Pageof 21

Showing results (21-30 of 202) with videos related to

Sort By:
Pageof 21
Oncotarget|December 3, 2014
ADAM10 and ADAM17: New players in trastuzumab tesistanceMichael J Duffy, John Crown, Maeve Mullooly
Seminars in Cancer Biology|July 6, 2020
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancerNicola Gaynor, John Crown, Denis M Collins
Methods in Molecular Biology (Clifton, N.J.)|September 8, 2011
Analysis of gene expression as relevant to cancer cells and circulating tumour cellsAnne M Friel, John Crown, Lorraine O'Driscoll
Investigational New Drugs|January 28, 2025
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630Minhong Tang, John Crown, Michael J Duffy
Targeted Oncology|August 15, 2025
MYC as a Target for Cancer Treatment: from Undruggable to Druggable?Michael J Duffy, Minhong Tang, John Crown
Medical Oncology (Northwood, London, England)|July 14, 2022
Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cellsShane O'Grady, John Crown, Michael J Duffy
The Oncologist|May 27, 2004
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experienceJohn Crown, Michael O'Leary, Wei-Seong Ooi
Breast Cancer Research and Treatment|March 23, 2018
Mutant p53 in breast cancer: potential as a therapeutic target and biomarkerMichael J Duffy, Naoise C Synnott, John Crown
Clinical Chemistry and Laboratory Medicine|April 15, 2021
Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?Michael J Duffy, Eleftherios P Diamandis, John Crown
International Journal of Cancer|May 15, 2012
Targeted therapy for triple-negative breast cancer: where are we?Michael J Duffy, Patricia M McGowan, John Crown
Pageof 21